Drug intelligence / Profile preview

KeraStat Cream

Development stage: Unknown
Lead developer: KeraNetics
Modality: Drug Delivery Systems
Administration: Topical

Overview

KeraStat Cream is an FDA-cleared medical device containing 5% keratin protein incorporated into a cream base. It is designed to maintain a moist wound environment for the management of partial thickness skin wounds, particularly radiation dermatitis in cancer patients undergoing radiotherapy. The product was developed in collaboration with the Wake Forest Institute for Regenerative Medicine and has been studied as a medical countermeasure against radiation injuries for the Department of Defense and the Biomedical Advanced Research and Development Authority.

Brand names: KeraStatKeraStat Cream

Beyond the preview

Go deeper on KeraStat Cream.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KeraStat Cream.

Explore the full profile